International Conference on Harmonisation (ICH) E6 and ICH E3, developed nearly 20 years ago, are the current regulatory guidance documents for developing clinical study protocols (CSPs) and clinical study reports (CSRs). Ambiguity in the guidelines, and recent public disclosure requirements mean that review and revision of these guidelines is warranted. In May 2014, EMWA assembled a group of experts, called the Budapest Working Group (BWG), and initiated a 2-year collaboration with a variety of stakeholders to review the two guidelines. The resulting recommendations should address the needs of the widest possible community; incorporate developments since the guidelines were first issued; and facilitate responsible clinical trial data sharing. In this first of three planned open-access publications, we explain the objectives of this project, present our 2-year project plan, and report on progress to date.
Nearly two decades have passed since the International Committee on Harmonisation (ICH) issued regulatory guidance documents for developing clinical study protocols (CSPs) and clinical study reports (CSRs), respectively ICH E6 and ICH E3. Since then, the evolving context of global pharmaceutical research and development and their applications means that review and revision of these guidelines is now required.
Public disclosure and transparency of clinical trial data
Despite the global drive towards public disclosure of clinical trial results, [1] [2] [3] underreporting of trials registered on the US FDA's http://www. ClinicalTrials.gov occurs. 4 For the 53 new medicines approved by the European Medicines Agency (EMA) in 2009-2011, nearly three-quarters of the related results were disclosed within 1 year of trial completion or regulatory approval, and nearly 90% by 31 January 2013. 5 Voluntary publication of trial data, combined with publication of summary clinical trial results on the EMA's EU Clinical Trials Register (http://www.clinicaltrialsregister.eu), has undoubtedly enhanced public disclosure and transparency in the EU. The EMA policy on publication of clinical data for medicinal products for human use, effective 1 January 2015, 6 will strengthen this trend by mandating stepwise disclosure of clinical data submitted under the centralised marketing authorisation procedure in the EU. A de novo review of ICH E3, conducted by current end-users, will provide recommendations to minimise ambiguity. The end product should not be a complete rewrite of the ICH E3 guideline because it generally suits its intended purpose. As ICH E3 links to many other guidance documents, including ICH E6 and other industry processes and procedures, the recommendations must anticipate a possible 'domino effect'. Oversight review of the de novo review recommendations will ensure appropriate handling of broader issues with collateral impact. Ultimately, stakeholder evaluation and support of the combined de novo and oversight reviews will ensure that the final recommendations address the needs of the widest possible community. As CSP guidance must address some CSP components that ultimately feed into ICH E3, a project to develop recommended CSP guidance will also be undertaken.
Consider the increased access to CSPs and CSRs Historically, the primary audience for CSPs and CSRs comprised investigators, industry insiders, and regulators. The Pharmaceutical Research and Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries and Associations (EFPIA) jointly developed Principles for Responsible Clinical Trial Data Sharing, which were implemented on 1 January 2014. 14 In addition, the EU's recently introduced disclosure and transparency policy (EMA policy effective 1 January 2015 6 ) increases the traditional audience for CSPs and CSRs. Academic and research groups can request access to datasets to attempt to reproduce study results, or they may perform their own analyses. In anticipation of this change, many pharmaceutical companies created websites for requesting clinical study data and established independent adjudication panels to assess the requests and ensure appropriate disclosure. Public access to CSPs and CSRs requires, above all, that individual study participants cannot be identified from published information. Developing targeted treatments, which focus research efforts on genetically suitable populations -effectively 'personalised medicine' research -will present challenges. Patients with rare conditions enrolled in small numbers at a particular site may be relatively easy to identify from their data. If an individual's pre-existing conditions are disclosed, this could preclude their eligibility for health insurance cover in some countries. Potentially, clinical trial data could also be used to influence reimbursement decisions in countries with 'free at the point of access' healthcare services or to exclude entire populations from health insurance coverage or state medical aid based on genetic predisposition.
Science and medicine are evidence-based disciplines, where peer-reviewed publication is held in high regard. Cited publications support fact and develop and inform scientific discussion. Professionals, who have Internet, library, and financial resources at their disposal, rarely have difficulties accessing the actual publications from a simple bibliographic reference. To aid transparency and to prevent exclusion of those without institutional resources, the wider audience for CSPs and CSRs must have access to the literature at little or no cost.
Finally, CSRs and CSPs that ultimately progress into a filing within a submission dossier must also continue to meet electronic data standards. 15 Align CSP content and ICH E3 (CSR content) ICH E6 and ICH E3 are inextricably linked, so a review of one requires a review of the other.
Currently, ICH E6 guidance for CSP development is minimal and open to interpretation. Detailed CSP guidance needs to be developed to improve reporting, optimise reproducibility, enhance transparency, and protect participants.
Currently, study objectives are often not clearly linked to endpoints. This not only raises issues of reproducibility but also confounds statistical analysis planning and reporting.
There is also no requirement that the rationale of the study design is documented. This is best captured when the protocol is being developed. Protocols are usually developed rapidly, so the responsible multidisciplinary team inevitably focuses on producing a final protocol in the shortest possible time. Recording how and why a particular aspect of a study design develops may be a low priority, but if not captured, can lead to reverse engineering when producing the CSR. A requirement to include rationale for design elements in the protocol will increase reporting accuracy and enhance transparency.
Steps must be taken early in the project lifecycle to meet the requirement for disclosure-ready CSRs. Patient identification numbers must not include a centre identifier that could enable individuals to be identified. Sponsors should be prompted to consider fundamental study set-up issues during protocol design because they lay the foundation for creating a disclosure-ready CSR.
Facilitate clear, fit-for-purpose information sharing Since ICH E6 and ICH E3 were developed, unwieldy paper-based systems have given way to multiple electronic systems. Information is electronically accessible and shared through professional and social media platforms. Subsequent interpretation and dissemination of resulting insights falls outside the remit of current statutory regulation. Clinical study data must be summarised with absolute clarity and at a level appropriate to support informed interpretation and minimise aberrant claims or criticisms.
To present high-level summary data for regulatory review, detailed data from constituent 'building block' CSRs are typically abstracted and repurposed for regulatory submission summary documents, which include the MAA in Europe, the New Drug Application in Japan and the USA, and the US biologic and device equivalents (Biologic Licensing Application and Product Marketing Application, respectively). The CSR must, however, completely summarise within-study data to allow later simplification. The widespread lack of understanding about this can complicate creation of a CSR. For example, although adverse effects are of ultimate regulatory interest in a submission summary document, the actual numbers of patients experiencing adverse events must first be summarised in the CSR. Ambiguity in ICH E3 guidance about displays of adverse events can lead to CSRs that summarise and report only the numbers of patients experiencing the events without detailing the actual events. This confounds the identification of patterns in event frequencies and compromises the description of individual laboratory abnormalities in the context of adverse events. Upcoming transparency regulations mean that incorrect interpretation of this guideline must come to an end; the guideline must include clear, directive language devoid of ambiguity.
Encourage a streamlined process for disclosure-ready CSRs Publicly disclosed integrated CSRs will include the CSR text portion (Sections 1-15 in the ICH E3 guideline numbering system), Appendix 16.1.1 (protocol and protocol amendments), Appendix 16.1.2 (sample case report form), and Appendix 16.1.9 (documentation of statistical methods). Patient data listings (Appendix 16.2) will not be disclosed. 6 The summarised data in Section 14 (tables, figures and graphs referred to but 16 with the understanding that these will inevitably continue to develop. Narratives should be moved to a nondisclosed appendix. Industry is currently debating a two-step process for submitting and then publishing clinical study results. The two-step process involves producing a submission-ready CSR that may contain data that must be removed after submission to produce the final disclosure-ready CSR. We propose that the CSR should be as disclosure-ready as possible from the outset to safeguard against inadvertent identification of participants, assure optimally timed public disclosure of clinical trial results, and be as cost efficient as possible.
Facilitate -not hinder -the process of licensing medicines Getting safe and effective medicines to market is in the best interests of all parties. The global population needs medicines and their approval should not be hampered by suboptimal data presentation. Regulatory reviewers appreciate clearly written and well-presented documents; clearly presented information helps them better understand the data and may ultimately streamline the regulatory review processes. Optimisations may include tabulating selected data currently presented in narrative form and increasing the use of graphs over summary tables to illustrate trends.
The Budapest Working Group: Methods for reviewing and developing the ICH E3 guideline and developing CSP guidance
In May 2014 EMWA assembled a group of experts, called the Budapest Working Group (BWG), and initiated a 2-year collaboration with a variety of stakeholders to review the ICH E3 and CSP guidelines (including E6). The roadmap for the BWG and stakeholder reviews resulting in final content recommendations are summarised in Figure 1 . Briefly, the project comprises four stages.
• Stage 1: Existing ICH E3 guidance will be reviewed and recommended updates developed.
New recommended CSP guidance will be developed and then reviewed. These tasks will be performed separately by an EMWA BWG de novo review and development team.
• Stage 2: The results of each de novo work exercise will be assessed by an EMWA BWG oversight evaluation team to ensure that it meets Good Clinical Practice requirements; transparency/disclosure requirements including responsible clinical trial data sharing; is aligned with the other relevant guidance documents; meets the needs of the international medical writing community; and is globally acceptable and in agreement with industry trends.
• Stage 3: Stakeholders will review the recommendations.
• Stage 4: Comments from stakeholders will be consolidated and integrated into the recommendations.
The outcomes of the stakeholder consultation will form the basis for the second open-access publication originating from this project, which will be published in Medical Writing in late 2015. Final content recommendations for ICH E3 and for CSP guidance, agreed by majority consensus with stakeholder parties, are expected to be published in the secondquarter of 2016 in a prominent open-access journal, such as BMJ Open. The update and reissue of ICH E3 and the issue of detailed ICH guidance for CSPs including any public consultation processes, are outside the scope of responsibility of the BWG.
Composition of the Budapest Working Group
The BWG collaboration includes professional associations, regulators, and key industry participants with expertise in ICH E3 and ICH E6 guidelines, CSP and CSR templates, and disclosure and transparency issues. In addition to the two main teams (de novo review and development team and oversight evaluation team), the BWG also includes a strategist who is working with the partner and stakeholder organisations and an experienced medical writer who is providing administrative support at all stages of the project.
Composition of the de novo review and development and oversight evaluation teams The E3 de novo review team comprises five members:
• Two freelance expert end-users of ICH E3 and ICH E6 (SH and DJ) who have a total of 36 years of regulatory medical writing experience and have written for large and small European, American, and Japanese sponsors, The E3 oversight evaluation team includes:
• A pharmaceutical company CSR and CSP template expert (WS) • A CRO transparency and disclosure expert (TF) • A consultant with expertise in global regulatory standards and industry trends (AG) • Representation from the American Medical Writers Association (AMWA) (AB).
Teams will remain the same for the CSP project, except for SH and WS who will exchange roles, SH to the oversight evaluation team and WS to the de novo development and review team. WS will develop the CSP guidance that will be subsequently reviewed by DJ and VF. The members of the BWG are listed in Table 1 .
Status of the review
Oversight evaluation is now complete for the ICH E3 review and is ongoing for the CSP content recommendations. A package of introductory material has been delivered to the stakeholders. The BWG anticipates completing its review and development work in January 2015. Stakeholder review of both documents will begin in March 2015 and will include:
• Regulators in all three ICH regions -EMA, the US FDA, and Japan's Pharmaceutical and Medical Devices Agency (PMDA) • Regulator outside the ICH region -Health Canada In addition, a number of stakeholders hold crossorganisational positions and contribute expertise and insights from three large pharmaceutical companies; the ICH E3 2012 question and answer working group; and TransCelerate Biopharma Inc. transparency effort.
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